New IBS drug shows promise in Mid-Stage trial
NCT ID NCT07519395
First seen May 03, 2026 · Last updated May 14, 2026 · Updated 2 times
Summary
This study tests a new drug called camlipixant in 420 adults with moderate-to-severe irritable bowel syndrome (IBS) that causes diarrhea or mixed bowel habits. Participants will receive either the drug or a placebo for 26 weeks to see if it reduces abdominal pain and improves stool consistency. The goal is to ease symptoms, not cure the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IRRITABLE BOWEL SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.